Cardiex Ltd (CDX) - Cash Flow Conversion Efficiency

Latest as of December 2024: -0.452x

Based on the latest financial reports, Cardiex Ltd (CDX) has a cash flow conversion efficiency ratio of -0.452x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.99 Million ≈ $-2.11 Million USD) by net assets (AU$6.60 Million ≈ $4.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CDX equity to assets ratio to measure how much of total assets are equity-financed.

Cardiex Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Cardiex Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Cardiex Ltd (CDX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Cardiex Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cardiex Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
PT Jaya Bersama Indo Tbk
JK:DUCK
-0.035x
Pasinex Resources Limited
F:PNX
-0.047x
Purefun Group AB
ST:PURE
0.088x
TCS Group Holdings Bhd
KLSE:0221
-0.056x
Daesang Corp Preference Shares
KO:001685
0.058x
Inbest Prime III Inmuebles SOCIMI S.A.
MC:YINB3
N/A
Fourth-Link Inc.
KQ:056730
0.000x
Oncosil Medical Ltd
AU:OSL
-1.814x

Annual Cash Flow Conversion Efficiency for Cardiex Ltd (2005–2024)

The table below shows the annual cash flow conversion efficiency of Cardiex Ltd from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Cardiex Ltd market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-06-30 AU$4.09 Million
≈ $2.89 Million
AU$-7.72 Million
≈ $-5.46 Million
-1.889x -115.76%
2023-06-30 AU$-1.00 Million
≈ $-708.11K
AU$-12.00 Million
≈ $-8.49 Million
11.987x +924.03%
2022-06-30 AU$6.61 Million
≈ $4.68 Million
AU$-9.62 Million
≈ $-6.80 Million
-1.455x -189.65%
2021-06-30 AU$7.91 Million
≈ $5.60 Million
AU$-3.97 Million
≈ $-2.81 Million
-0.502x -73.83%
2020-06-30 AU$5.88 Million
≈ $4.16 Million
AU$-1.70 Million
≈ $-1.20 Million
-0.289x +12.33%
2019-06-30 AU$6.95 Million
≈ $4.92 Million
AU$-2.29 Million
≈ $-1.62 Million
-0.330x -630.02%
2018-06-30 AU$4.60 Million
≈ $3.25 Million
AU$-207.49K
≈ $-146.82K
-0.045x +98.04%
2017-06-30 AU$1.33 Million
≈ $939.99K
AU$-3.07 Million
≈ $-2.17 Million
-2.308x -47.31%
2016-06-30 AU$3.14 Million
≈ $2.22 Million
AU$-4.92 Million
≈ $-3.48 Million
-1.567x -245.40%
2015-06-30 AU$4.33 Million
≈ $3.07 Million
AU$-1.97 Million
≈ $-1.39 Million
-0.454x -9.20%
2014-06-30 AU$3.28 Million
≈ $2.32 Million
AU$-1.36 Million
≈ $-965.08K
-0.415x -214.06%
2013-06-30 AU$4.88 Million
≈ $3.45 Million
AU$1.78 Million
≈ $1.26 Million
0.364x +158.04%
2012-06-30 AU$1.88 Million
≈ $1.33 Million
AU$-1.18 Million
≈ $-836.57K
-0.627x -0.39%
2011-06-30 AU$3.03 Million
≈ $2.15 Million
AU$-1.90 Million
≈ $-1.34 Million
-0.625x +9.43%
2010-06-30 AU$3.74 Million
≈ $2.64 Million
AU$-2.58 Million
≈ $-1.82 Million
-0.690x -402.75%
2009-06-30 AU$4.65 Million
≈ $3.29 Million
AU$-637.56K
≈ $-451.11K
-0.137x +78.34%
2008-06-30 AU$5.96 Million
≈ $4.22 Million
AU$-3.78 Million
≈ $-2.67 Million
-0.634x -32.50%
2007-06-30 AU$9.38 Million
≈ $6.64 Million
AU$-4.49 Million
≈ $-3.18 Million
-0.478x -61.50%
2006-06-30 AU$14.41 Million
≈ $10.19 Million
AU$-4.27 Million
≈ $-3.02 Million
-0.296x -126.85%
2005-06-30 AU$18.80 Million
≈ $13.30 Million
AU$-2.45 Million
≈ $-1.74 Million
-0.131x --

About Cardiex Ltd

AU:CDX Australia Medical Devices
Market Cap
$13.23 Million
AU$18.70 Million AUD
Market Cap Rank
#26310 Global
#1193 in Australia
Share Price
AU$0.03
Change (1 day)
-5.56%
52-Week Range
AU$0.03 - AU$0.04
All Time High
AU$2.74
About

Conneqt Health Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffnes… Read more